pubmed-article:304785 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:304785 | lifeskim:mentions | umls-concept:C0030817 | lld:lifeskim |
pubmed-article:304785 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:304785 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
pubmed-article:304785 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:304785 | pubmed:dateCreated | 1978-4-26 | lld:pubmed |
pubmed-article:304785 | pubmed:abstractText | Immunological effects of D- and D,L-penicillamine (PA) were studied in efforts to develop assays for synthetic D or D,L analogs and to contribute to the understanding of the mechanism(s) of action of D-PA in rheumatoid arthritis. At the highest doses tolerated by mice, D,L-PA did not significantly inhibit the development of haemagglutinating antibodies in vivo. In studies in vitro with T lymphocytes, D-PA at 1 mM concentration inhibited both concanavalin A- and phytohaemagglutinin-induced transformation as assayed by [3H]thymidine incorporation, but D-PA concentrations of 5 mM were required to inhibit concanavalin A-induced amino acid uptake. No effect of D-PA was observed either on the induction of cytotoxic T cells or on the attack of specifically sensitized T cells on target cells. It is of interest that D-PA at 1 mM concentration did inhibit lipopolysaccharide-induced transformation, which predominately stimulates B lymphocytes. The effects of PA on the induced transformation of T and B cells deserve further attention for studies with analogs of PA. | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:language | eng | lld:pubmed |
pubmed-article:304785 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:304785 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:304785 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:304785 | pubmed:month | Nov | lld:pubmed |
pubmed-article:304785 | pubmed:issn | 0009-9104 | lld:pubmed |
pubmed-article:304785 | pubmed:author | pubmed-author:HarshmanSS | lld:pubmed |
pubmed-article:304785 | pubmed:author | pubmed-author:GalloA AAA | lld:pubmed |
pubmed-article:304785 | pubmed:author | pubmed-author:ChenD MDM | lld:pubmed |
pubmed-article:304785 | pubmed:author | pubmed-author:GIBBSD CDC | lld:pubmed |
pubmed-article:304785 | pubmed:author | pubmed-author:Di SabatoGG | lld:pubmed |
pubmed-article:304785 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:304785 | pubmed:volume | 30 | lld:pubmed |
pubmed-article:304785 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:304785 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:304785 | pubmed:pagination | 317-22 | lld:pubmed |
pubmed-article:304785 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-A... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-M... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-M... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-P... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-A... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-D... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-L... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-I... | lld:pubmed |
pubmed-article:304785 | pubmed:meshHeading | pubmed-meshheading:304785-T... | lld:pubmed |
pubmed-article:304785 | pubmed:year | 1977 | lld:pubmed |
pubmed-article:304785 | pubmed:articleTitle | Some immunological effects of penicillamine. | lld:pubmed |
pubmed-article:304785 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:304785 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |